Myomo (MYO) Corporate presentation summary

Strategic positioning and market opportunity

• Created a new product category with the MyoPro myoelectric orthosis, establishing first-mover advantage in a large and growing market for upper limb paralysis solutions.

• CMS reimbursement and new payer contracts are expanding patient access, with growing revenues from recurring patient sources and an attractive margin profile.

• The addressable market is substantial, with 800,000 annual strokes in the U.S. and 3.8 million people living with upper extremity impairment; 400,000 to 800,000 patients may qualify for MyoPro.

Product innovation and clinical evidence

• MyoPro is a wearable, non-invasive powered arm brace using advanced EMG signal processing and proprietary algorithms to restore arm function.

• The device is protected by 35 patents valid through 2042, with additional patents pending, and the MyoPro 2x launched in April to improve user experience.

• Clinical studies and systematic reviews show statistically significant and clinically meaningful improvements in upper extremity function for users, with ongoing RCTs to further validate outcomes.

Reimbursement, payer contracts, and market access

• HCPCS codes L8701 and L8702 for MyoPro are in the brace benefit category, with updated CMS fees effective January 2026 ($34,970 and $68,802, respectively).

• Contracts with commercial payers now cover over 80 million lives, with multi-state contracts in progress and more than 100 VA medical centers ordering MyoPros.

• Covered lives are projected to reach 158 million by July 2026, pending completion of new contracts.